Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-07T14:59:14.795Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of cibenzoline for hypertrophic obstructive cardiomyopathy in paediatric patients with RAS/MAPK pathway syndromes

Published online by Cambridge University Press:  12 October 2022

Kota Watanabe Open the ORCID record for Kota Watanabe [Opens in a new window] ,
Yuji Maruo  and
Atsuhito Takeda Open the ORCID record for Atsuhito Takeda [Opens in a new window]
Kota Watanabe
Affiliation:
Pediatrics, Kitami Red Cross Hospital, North 6-East 2, Kitami, Hokkaido, Japan
Yuji Maruo
Affiliation:
Pediatrics, Kitami Red Cross Hospital, North 6-East 2, Kitami, Hokkaido, Japan
Atsuhito Takeda*
Affiliation:
Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
*
Author for correspondence: Atsuhito Takeda, Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan. E-mail: a-takeda@med.hokudai.ac.jp
Get access Rights & Permissions [Opens in a new window]

Abstract

RASopathies – caused by mutations in the RAS/MAPK signaling pathway – are frequently associated with cardiac diseases, such as hypertrophic obstructive cardiomyopathy. Although cibenzoline is useful for adult hypertrophic obstructive cardiomyopathy patients, little is known about its effect in children. Here, we report two paediatric cases of hypertrophic obstructive cardiomyopathy associated with RASopathies where the condition was improved by cibenzoline.

Keywords

Hypertrophic obstructive cardiomyopathyRASopathiescibenzoline
Type
Brief Report
Information
Cardiology in the Young , Volume 33 , Issue 6 , June 2023 , pp. 1007 - 1009
Check for updates
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wolf, CM, Zenker, M, Burkitt-Wright, E, et al. Management of cardiac aspects in children with Noonan syndrome - results from a European clinical practice survey among paediatric cardiologists. Eur J Med Genet 2021; 65: 104372.CrossRefGoogle ScholarPubMed
Sherrid, M, Delia, E, Dwyer, E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988; 62: 1085–1088.CrossRefGoogle ScholarPubMed
Hamada, M, Shigematsu, Y, Ikeda, S, Nakamura, M, Ohshima, K, Ogimoto, A. Impact of cibenzoline treatment on left ventricular remodeling and prognosis in hypertrophic obstructive cardiomyopathy. ESC Heart Fail 2021; 8: 4832–4842.CrossRefGoogle ScholarPubMed
Hamada, M, Shigematsu, Y, Ikeda, S, et al. Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520–1524.CrossRefGoogle Scholar
Gwathmey, JK, Warren, SE, Briggs, GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest 1991; 87: 1023–1031.CrossRefGoogle ScholarPubMed
Palmiter, KA, Solaro, RJ. Molecular mechanisms regulating the myofilament response to Ca2+: implications of mutation causal for familial hypertrophic cardiomyopathy. Basic Res Cardiol 1997; 92: 63–74.CrossRefGoogle ScholarPubMed
Noordam, C. Growth hormone and the heart in Noonan syndrome. Horm Res 2009; 72 Suppl, 2: 49–51.Google ScholarPubMed
Seo, GH, Yoo, HW. Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 2018; 23: 176–181.CrossRefGoogle ScholarPubMed
Noonan, JA, Kappelgaard, AM. The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 2015; 83: 157–166.CrossRefGoogle ScholarPubMed
Jo, KJ, Kim, YM, Yoon, JY, et al. Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome. Korean J Pediatr 2019; 62: 274–280.CrossRefGoogle ScholarPubMed